Page 3 - Les meilleurs doctors traitant la maladie suivante : Сarcinomatose - TOP -66 des médecins

Plus de 30 ans d'expérience en immunologie – Le Dr Jaunalksne est spécialisée en virothérapie, une approche de pointe en immunologie.

• Diriger le centre d'immunologie clinique de l'hôpital universitaire clinique Pauls Stradins
• Être diplômée de l'Institut de médecine de Riga avec un internat en médecine interne
• Se concentrer sur les traitements innovants par virothérapie

Dr. Zohar Dotan is Head of the Urology Department at Sheba Medical Center. He is a leading uro-oncologist and a pioneer of robotic and laparoscopic urologic surgery in Israel.

He has authored more than 50 scientific publications. He is a regular speaker at international conferences. He has received awards from the American Association of Clinical Surgery, including recognition for research in prostate cancer treatment.

Leadership and credentials: Head of the Israeli Uro-Oncology Society. Assistant Professor at Tel Aviv University. Member of the Israeli, American, and European Urological Associations. Training: MD from Tel Aviv University and a PhD in Genetics. Urology residency at Sheba Medical Center. Fellowship in uro-oncology and laparoscopic surgery at Memorial Sloan Kettering, New York.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Dr. Mohamed Mahmoud Abdelhakim is Head of Radiation Oncology at Shefa al Orman Hospital, Luxor. He is Professor of Radiation Oncology at the National Cancer Institute, Cairo University. He previously served as Associate Professor (2015–2020), Lecturer (2010–2015), Assistant Lecturer (2003–2009), and Resident (2000–2003). He also worked as a Specialist at Gharbia Cancer Society.

He treats inpatients and outpatients with breast, soft tissue sarcoma, lymphoma, gynecologic, gastrointestinal, genitourinary, and CNS tumors. His skills include image-guided brachytherapy, IMRT, VMAT, SRS, and SBRT. He performs conventional and CT-based planning and 3D-CRT. He works with cobalt and linear accelerators and electron beam therapy. He provides HDR and LDR intracavitary and interstitial brachytherapy. He also performs stereotactic radiotherapy, total body irradiation, and total skin irradiation.

Member: Egyptian Cancer Society, ESTRO, ESMO.

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Spécialisé dans les chirurgies cancéreuses complexes, y compris les interventions du pancréas et des voies biliaires aux hôpitaux Büyük Anadolu.

• Expertise en chirurgie oncologique avec un focus sur les cancers gastro-intestinaux
• Réaliser des chirurgies avancées du cancer du sein et de la thyroïde
• Qualifié dans les techniques de chirurgie bariatrique et métabolique

Le Dr Joseba Rebollo Liceaga possède plus de 30 ans d'expertise en oncologie, se spécialisant dans les approches de traitement multidisciplinaires.

• Diriger le service d'oncologie dans plusieurs hôpitaux prestigieux
• Rédiger des recherches sur l'électrochimiothérapie
• Spécialiste en oncologie médicale à la Clínica Universidad de Navarra
• Pratiquer actuellement à Quirónsalud Alicante

Spécialisé en radio-oncologie à l'Université de Marmara – l'une des principales facultés de médecine de Turquie.

• Diplômé de la Faculté de Médecine de l'Université de Marmara
• Formation spécialisée achevée en radio-oncologie
• Travailler à l'Hôpital Emsey – un centre de cancérologie de premier plan

Le Dr Raj a pratiqué plus de 50 000 interventions chirurgicales oncologiques sur 19 ans, se spécialisant en oncologie chirurgicale mammaire et thoracique au HCG Manavata Cancer Centre.

• Formé au Tata Memorial Hospital et au Royal College of Surgeons d'Edimbourg
• Impliqué dans plus de 200 essais cliniques, y compris des études de phases 1 à 3
• Professeur en surspécialité DNB en oncologie chirurgicale et chirurgie mammaire
• Mettre l'accent sur l'amélioration de la qualité de vie des patients parallèlement au traitement

Le Dr Shruti Kate est spécialisée dans les traitements avancés du cancer, notamment l'immunothérapie et la thérapie métronomique. Elle a été formée au Tata Memorial Hospital, le principal centre de cancérologie de l'Inde.

• Être experte des cancers du poumon, du sein et gynécologiques
• Être membre de l'ASCO, de l'ESMO et d'autres grandes sociétés d'oncologie
• Présenter des recherches sur le cancer du poumon lors de la Conférence mondiale sur le cancer du poumon
• Utiliser des approches innovantes pour les cas de cancer avancés

Plus de 30 000 examens TEP réalisés et 1 000 patients atteints de cancer de la thyroïde traités – le Dr Borde est spécialisé en médecine nucléaire au HCG Manavata Cancer Centre.

• 12 ans d'expérience en médecine nucléaire
• Maîtrise des thérapies au radioïode et au Lu-177 RN
• Expert dans tous les types de scintigraphies nucléaires et TEP-TDM
• Articles publiés dans diverses revues médicales

Expert en oncologie doté d'un solide bagage académique, enseignant aux étudiants en médecine et dirigeant la recherche postuniversitaire au HM CIOCC.

• Se spécialiser en oncologie orale et maxillo-faciale
• Enseigner un large éventail de sujets liés à l'oncologie
• Diriger la recherche postuniversitaire en oncologie clinique et appliquée
• Encadrer les étudiants en médecine et les résidents dans les pratiques oncologiques

Forte de plus de 20 ans d'expérience consacrés à l'hématologie et l'oncologie pédiatriques, le Dr Lopez Ibor dirige l'unité d'hématologie et d'oncologie pédiatriques de l'hôpital HM Montepríncipe.

• Se spécialiser dans les tumeurs osseuses et cérébrales, la leucémie et les maladies hématologiques
• Se former à l'Université du Maryland en hématologie et oncologie pédiatriques
• Auteur de nombreuses publications scientifiques nationales et internationales
• Auparavant, diriger la même unité à l'Hospital Universitario Clínica San Rafael